Immuneering (NASDAQ:IMRX) Stock Rating Upgraded by Wall Street Zen

Immuneering (NASDAQ:IMRX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

A number of other analysts also recently weighed in on IMRX. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Immuneering in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $5.53 on Friday. The company has a 50 day simple moving average of $5.22 and a 200 day simple moving average of $5.76. The firm has a market cap of $357.51 million, a PE ratio of -4.01 and a beta of 0.43. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.13. As a group, research analysts anticipate that Immuneering will post -1.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immuneering

A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in Immuneering in the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Immuneering in the 4th quarter worth about $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in Immuneering in the 3rd quarter worth about $35,000. Future Financial Wealth Managment LLC purchased a new stake in Immuneering in the 3rd quarter worth about $35,000. Finally, SummitTX Capital L.P. purchased a new stake in Immuneering in the 4th quarter worth about $69,000. 67.65% of the stock is currently owned by institutional investors.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.